ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000352

Amantadine Use Associated with Impulse Control Disorders in Parkinson Disease in Cross-Sectional Study

Identifieur interne : 000352 ( PascalFrancis/Corpus ); précédent : 000351; suivant : 000353

Amantadine Use Associated with Impulse Control Disorders in Parkinson Disease in Cross-Sectional Study

Auteurs : Daniel Weintraub ; Mandy Sohr ; Marc N. Potenza ; Andrew D. Siderowf ; Mark Stacy ; Valerie Voon ; Jacqueline Whetteckey ; Glen R. Wunderlich ; Anthony E. Lang

Source :

Annals of neurology [ 0364-5134 ] ; 2010.

RBID : Pascal:11-0060434

Descripteurs français

Pascal (Inist)
- Trouble du contrôle des impulsions, Maladie de Parkinson, Pathologie du système nerveux, Amantadine, Etude transversale.

English descriptors

KwdEn :
- Amantadine, Cross sectional study, Impulse control disorder, Nervous system diseases, Parkinson disease.

Abstract

A recent controlled clinical trial suggested a role for amantadine as a treatment for pathological gambling in patients with Parkinson disease (PD). Analyzing data from a large cross-sectional study of impulse control disorders (ICDs) in PD, amantadine use (n = 728), vs no amantadine use (n = 2,357), was positively associated with a diagnosis of any ICD (17.6% vs 12.4%, p < 0.001) and compulsive gambling specifically (7.4% vs 4.2%, p < 0.001). This amantadine association remained after controlling for covariates of amantadine use, including both dopamine agonist use and levodopa dosage. Further research, including larger clinical trials, is needed to assess the role of amantadine in the development and treatment of ICDs in PD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0364-5134`
A02	`01`			`@0 ANNED3`
A03		`1`		`@0 Ann. neurol.`
A05				`@2 68`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Amantadine Use Associated with Impulse Control Disorders in Parkinson Disease in Cross-Sectional Study`
A11	`01`	`1`		`@1 WEINTRAUB (Daniel)`
A11	`02`	`1`		`@1 SOHR (Mandy)`
A11	`03`	`1`		`@1 POTENZA (Marc N.)`
A11	`04`	`1`		`@1 SIDEROWF (Andrew D.)`
A11	`05`	`1`		`@1 STACY (Mark)`
A11	`06`	`1`		`@1 VOON (Valerie)`
A11	`07`	`1`		`@1 WHETTECKEY (Jacqueline)`
A11	`08`	`1`		`@1 WUNDERLICH (Glen R.)`
A11	`09`	`1`		`@1 LANG (Anthony E.)`
A14	`01`			`@1 Department of Psychiatry, University of Pennsylvania School of Medicine @2 Philadelphia, PA @3 USA @Z 1 aut.`
A14	`02`			`@1 Department of Neurology, University of Pennsylvania School of Medicine @2 Philadelphia, PA @3 USA @Z 1 aut. @Z 4 aut.`
A14	`03`			`@1 Philadelphia Veterans Affairs Medical Center @2 Philadelphia, PA; @3 USA @Z 1 aut.`
A14	`04`			`@1 Boehringer Ingelheim Pharma GmbH & Co. KG @2 Ingelheim @3 DEU @Z 2 aut.`
A14	`05`			`@1 Department of Psychiatry, Yale University School of Medicine @2 New Haven, CT @3 USA @Z 3 aut.`
A14	`06`			`@1 Department of Child Study, Yale University School of Medicine @2 New Haven, CT @3 USA @Z 3 aut.`
A14	`07`			`@1 Department of Neurobiology, Yale University School of Medicine @2 New Haven, CT @3 USA @Z 3 aut.`
A14	`08`			`@1 Department of Neurology, Duke University Medical Center @2 Durham, NC @3 USA @Z 5 aut.`
A14	`09`			`@1 University of Cambridge @2 Cambridge @3 GBR @Z 6 aut.`
A14	`10`			`@1 Boehringer Ingelheim Pharmaceuticals, Inc. @2 Ridgefield, CT @3 USA @Z 7 aut.`
A14	`11`			`@1 Boehringer Ingelheim (Canada) Ltd @2 Burlington, Ontario @3 CAN @Z 8 aut.`
A14	`12`			`@1 Department of Neurology, University of Toronto @2 Toronto, Ontario @3 CAN @Z 9 aut.`
A20				`@1 963-968`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 16555 @5 354000193558180260`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 20 ref.`
A47	`01`	`1`		`@0 11-0060434`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Annals of neurology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 A recent controlled clinical trial suggested a role for amantadine as a treatment for pathological gambling in patients with Parkinson disease (PD). Analyzing data from a large cross-sectional study of impulse control disorders (ICDs) in PD, amantadine use (n = 728), vs no amantadine use (n = 2,357), was positively associated with a diagnosis of any ICD (17.6% vs 12.4%, p < 0.001) and compulsive gambling specifically (7.4% vs 4.2%, p < 0.001). This amantadine association remained after controlling for covariates of amantadine use, including both dopamine agonist use and levodopa dosage. Further research, including larger clinical trials, is needed to assess the role of amantadine in the development and treatment of ICDs in PD.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Trouble du contrôle des impulsions @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Impulse control disorder @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Trastorno control impulso @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Amantadine @2 NK @2 FR @5 09`
C03	`04`	`X`	`ENG`	`@0 Amantadine @2 NK @2 FR @5 09`
C03	`04`	`X`	`SPA`	`@0 Amantadina @2 NK @2 FR @5 09`
C03	`05`	`X`	`FRE`	`@0 Etude transversale @5 10`
C03	`05`	`X`	`ENG`	`@0 Cross sectional study @5 10`
C03	`05`	`X`	`SPA`	`@0 Estudio transversal @5 10`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 038`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 11-0060434 INIST
ET :	Amantadine Use Associated with Impulse Control Disorders in Parkinson Disease in Cross-Sectional Study
AU :	WEINTRAUB (Daniel); SOHR (Mandy); POTENZA (Marc N.); SIDEROWF (Andrew D.); STACY (Mark); VOON (Valerie); WHETTECKEY (Jacqueline); WUNDERLICH (Glen R.); LANG (Anthony E.)
AF :	Department of Psychiatry, University of Pennsylvania School of Medicine/Philadelphia, PA/Etats-Unis (1 aut.); Department of Neurology, University of Pennsylvania School of Medicine/Philadelphia, PA/Etats-Unis (1 aut., 4 aut.); Philadelphia Veterans Affairs Medical Center/Philadelphia, PA;/Etats-Unis (1 aut.); Boehringer Ingelheim Pharma GmbH & Co. KG/Ingelheim/Allemagne (2 aut.); Department of Psychiatry, Yale University School of Medicine/New Haven, CT/Etats-Unis (3 aut.); Department of Child Study, Yale University School of Medicine/New Haven, CT/Etats-Unis (3 aut.); Department of Neurobiology, Yale University School of Medicine/New Haven, CT/Etats-Unis (3 aut.); Department of Neurology, Duke University Medical Center/Durham, NC/Etats-Unis (5 aut.); University of Cambridge/Cambridge/Royaume-Uni (6 aut.); Boehringer Ingelheim Pharmaceuticals, Inc./Ridgefield, CT/Etats-Unis (7 aut.); Boehringer Ingelheim (Canada) Ltd/Burlington, Ontario/Canada (8 aut.); Department of Neurology, University of Toronto/Toronto, Ontario/Canada (9 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Annals of neurology; ISSN 0364-5134; Coden ANNED3; Etats-Unis; Da. 2010; Vol. 68; No. 6; Pp. 963-968; Bibl. 20 ref.
LA :	Anglais
EA :	A recent controlled clinical trial suggested a role for amantadine as a treatment for pathological gambling in patients with Parkinson disease (PD). Analyzing data from a large cross-sectional study of impulse control disorders (ICDs) in PD, amantadine use (n = 728), vs no amantadine use (n = 2,357), was positively associated with a diagnosis of any ICD (17.6% vs 12.4%, p < 0.001) and compulsive gambling specifically (7.4% vs 4.2%, p < 0.001). This amantadine association remained after controlling for covariates of amantadine use, including both dopamine agonist use and levodopa dosage. Further research, including larger clinical trials, is needed to assess the role of amantadine in the development and treatment of ICDs in PD.
CC :	002B17; 002B17G
FD :	Trouble du contrôle des impulsions; Maladie de Parkinson; Pathologie du système nerveux; Amantadine; Etude transversale
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Impulse control disorder; Parkinson disease; Nervous system diseases; Amantadine; Cross sectional study
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Trastorno control impulso; Parkinson enfermedad; Sistema nervioso patología; Amantadina; Estudio transversal
LO :	INIST-16555.354000193558180260
ID :	11-0060434

Links to Exploration step

Pascal:11-0060434

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Amantadine Use Associated with Impulse Control Disorders in Parkinson Disease in Cross-Sectional Study</title>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Philadelphia Veterans Affairs Medical Center</s1>
<s2>Philadelphia, PA;</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sohr, Mandy" sort="Sohr, Mandy" uniqKey="Sohr M" first="Mandy" last="Sohr">Mandy Sohr</name>
<affiliation><inist:fA14 i1="04"><s1>Boehringer Ingelheim Pharma GmbH & Co. KG</s1>
<s2>Ingelheim</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Psychiatry, Yale University School of Medicine</s1>
<s2>New Haven, CT</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>Department of Child Study, Yale University School of Medicine</s1>
<s2>New Haven, CT</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurobiology, Yale University School of Medicine</s1>
<s2>New Haven, CT</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
<affiliation><inist:fA14 i1="08"><s1>Department of Neurology, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name>
<affiliation><inist:fA14 i1="09"><s1>University of Cambridge</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Whetteckey, Jacqueline" sort="Whetteckey, Jacqueline" uniqKey="Whetteckey J" first="Jacqueline" last="Whetteckey">Jacqueline Whetteckey</name>
<affiliation><inist:fA14 i1="10"><s1>Boehringer Ingelheim Pharmaceuticals, Inc.</s1>
<s2>Ridgefield, CT</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wunderlich, Glen R" sort="Wunderlich, Glen R" uniqKey="Wunderlich G" first="Glen R." last="Wunderlich">Glen R. Wunderlich</name>
<affiliation><inist:fA14 i1="11"><s1>Boehringer Ingelheim (Canada) Ltd</s1>
<s2>Burlington, Ontario</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><inist:fA14 i1="12"><s1>Department of Neurology, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0060434</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 11-0060434 INIST</idno>
<idno type="RBID">Pascal:11-0060434</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000352</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Amantadine Use Associated with Impulse Control Disorders in Parkinson Disease in Cross-Sectional Study</title>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Philadelphia Veterans Affairs Medical Center</s1>
<s2>Philadelphia, PA;</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sohr, Mandy" sort="Sohr, Mandy" uniqKey="Sohr M" first="Mandy" last="Sohr">Mandy Sohr</name>
<affiliation><inist:fA14 i1="04"><s1>Boehringer Ingelheim Pharma GmbH & Co. KG</s1>
<s2>Ingelheim</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Psychiatry, Yale University School of Medicine</s1>
<s2>New Haven, CT</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>Department of Child Study, Yale University School of Medicine</s1>
<s2>New Haven, CT</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurobiology, Yale University School of Medicine</s1>
<s2>New Haven, CT</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
<affiliation><inist:fA14 i1="08"><s1>Department of Neurology, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name>
<affiliation><inist:fA14 i1="09"><s1>University of Cambridge</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Whetteckey, Jacqueline" sort="Whetteckey, Jacqueline" uniqKey="Whetteckey J" first="Jacqueline" last="Whetteckey">Jacqueline Whetteckey</name>
<affiliation><inist:fA14 i1="10"><s1>Boehringer Ingelheim Pharmaceuticals, Inc.</s1>
<s2>Ridgefield, CT</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wunderlich, Glen R" sort="Wunderlich, Glen R" uniqKey="Wunderlich G" first="Glen R." last="Wunderlich">Glen R. Wunderlich</name>
<affiliation><inist:fA14 i1="11"><s1>Boehringer Ingelheim (Canada) Ltd</s1>
<s2>Burlington, Ontario</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><inist:fA14 i1="12"><s1>Department of Neurology, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine</term>
<term>Cross sectional study</term>
<term>Impulse control disorder</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Trouble du contrôle des impulsions</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Amantadine</term>
<term>Etude transversale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A recent controlled clinical trial suggested a role for amantadine as a treatment for pathological gambling in patients with Parkinson disease (PD). Analyzing data from a large cross-sectional study of impulse control disorders (ICDs) in PD, amantadine use (n = 728), vs no amantadine use (n = 2,357), was positively associated with a diagnosis of any ICD (17.6% vs 12.4%, p < 0.001) and compulsive gambling specifically (7.4% vs 4.2%, p < 0.001). This amantadine association remained after controlling for covariates of amantadine use, including both dopamine agonist use and levodopa dosage. Further research, including larger clinical trials, is needed to assess the role of amantadine in the development and treatment of ICDs in PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0364-5134</s0>
</fA01>
<fA02 i1="01"><s0>ANNED3</s0>
</fA02>
<fA03 i2="1"><s0>Ann. neurol.</s0>
</fA03>
<fA05><s2>68</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Amantadine Use Associated with Impulse Control Disorders in Parkinson Disease in Cross-Sectional Study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>WEINTRAUB (Daniel)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SOHR (Mandy)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>POTENZA (Marc N.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SIDEROWF (Andrew D.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>STACY (Mark)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>VOON (Valerie)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>WHETTECKEY (Jacqueline)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>WUNDERLICH (Glen R.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>LANG (Anthony E.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Philadelphia Veterans Affairs Medical Center</s1>
<s2>Philadelphia, PA;</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Boehringer Ingelheim Pharma GmbH & Co. KG</s1>
<s2>Ingelheim</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Psychiatry, Yale University School of Medicine</s1>
<s2>New Haven, CT</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Child Study, Yale University School of Medicine</s1>
<s2>New Haven, CT</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Neurobiology, Yale University School of Medicine</s1>
<s2>New Haven, CT</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Department of Neurology, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>University of Cambridge</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Boehringer Ingelheim Pharmaceuticals, Inc.</s1>
<s2>Ridgefield, CT</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Boehringer Ingelheim (Canada) Ltd</s1>
<s2>Burlington, Ontario</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Department of Neurology, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>963-968</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16555</s2>
<s5>354000193558180260</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>20 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0060434</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Annals of neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>A recent controlled clinical trial suggested a role for amantadine as a treatment for pathological gambling in patients with Parkinson disease (PD). Analyzing data from a large cross-sectional study of impulse control disorders (ICDs) in PD, amantadine use (n = 728), vs no amantadine use (n = 2,357), was positively associated with a diagnosis of any ICD (17.6% vs 12.4%, p < 0.001) and compulsive gambling specifically (7.4% vs 4.2%, p < 0.001). This amantadine association remained after controlling for covariates of amantadine use, including both dopamine agonist use and levodopa dosage. Further research, including larger clinical trials, is needed to assess the role of amantadine in the development and treatment of ICDs in PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Trouble du contrôle des impulsions</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Impulse control disorder</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Trastorno control impulso</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Amantadine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Amantadine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Amantadina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Etude transversale</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Cross sectional study</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estudio transversal</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>038</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 11-0060434 INIST</NO>
<ET>Amantadine Use Associated with Impulse Control Disorders in Parkinson Disease in Cross-Sectional Study</ET>
<AU>WEINTRAUB (Daniel); SOHR (Mandy); POTENZA (Marc N.); SIDEROWF (Andrew D.); STACY (Mark); VOON (Valerie); WHETTECKEY (Jacqueline); WUNDERLICH (Glen R.); LANG (Anthony E.)</AU>
<AF>Department of Psychiatry, University of Pennsylvania School of Medicine/Philadelphia, PA/Etats-Unis (1 aut.); Department of Neurology, University of Pennsylvania School of Medicine/Philadelphia, PA/Etats-Unis (1 aut., 4 aut.); Philadelphia Veterans Affairs Medical Center/Philadelphia, PA;/Etats-Unis (1 aut.); Boehringer Ingelheim Pharma GmbH & Co. KG/Ingelheim/Allemagne (2 aut.); Department of Psychiatry, Yale University School of Medicine/New Haven, CT/Etats-Unis (3 aut.); Department of Child Study, Yale University School of Medicine/New Haven, CT/Etats-Unis (3 aut.); Department of Neurobiology, Yale University School of Medicine/New Haven, CT/Etats-Unis (3 aut.); Department of Neurology, Duke University Medical Center/Durham, NC/Etats-Unis (5 aut.); University of Cambridge/Cambridge/Royaume-Uni (6 aut.); Boehringer Ingelheim Pharmaceuticals, Inc./Ridgefield, CT/Etats-Unis (7 aut.); Boehringer Ingelheim (Canada) Ltd/Burlington, Ontario/Canada (8 aut.); Department of Neurology, University of Toronto/Toronto, Ontario/Canada (9 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Annals of neurology; ISSN 0364-5134; Coden ANNED3; Etats-Unis; Da. 2010; Vol. 68; No. 6; Pp. 963-968; Bibl. 20 ref.</SO>
<LA>Anglais</LA>
<EA>A recent controlled clinical trial suggested a role for amantadine as a treatment for pathological gambling in patients with Parkinson disease (PD). Analyzing data from a large cross-sectional study of impulse control disorders (ICDs) in PD, amantadine use (n = 728), vs no amantadine use (n = 2,357), was positively associated with a diagnosis of any ICD (17.6% vs 12.4%, p < 0.001) and compulsive gambling specifically (7.4% vs 4.2%, p < 0.001). This amantadine association remained after controlling for covariates of amantadine use, including both dopamine agonist use and levodopa dosage. Further research, including larger clinical trials, is needed to assess the role of amantadine in the development and treatment of ICDs in PD.</EA>
<CC>002B17; 002B17G</CC>
<FD>Trouble du contrôle des impulsions; Maladie de Parkinson; Pathologie du   système nerveux; Amantadine; Etude transversale</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Impulse control disorder; Parkinson disease; Nervous system diseases; Amantadine; Cross sectional study</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Trastorno control impulso; Parkinson enfermedad; Sistema nervioso patología; Amantadina; Estudio transversal</SD>
<LO>INIST-16555.354000193558180260</LO>
<ID>11-0060434</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000352 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000352 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:11-0060434
   |texte=   Amantadine Use Associated with Impulse Control Disorders in Parkinson Disease in Cross-Sectional Study
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Amantadine Use Associated with Impulse Control Disorders in Parkinson Disease in Cross-Sectional Study

Amantadine Use Associated with Impulse Control Disorders in Parkinson Disease in Cross-Sectional Study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri